ProCE Banner Activity

Molecular Features in Gynecologic Cancers and the Optimal Use of PARP Inhibitors

Clinical Thought
Read experts’ thoughts on molecular characteristics in the management of gynecologic cancers and the optimal use of PARP inhibitors based on patient and disease characteristics.

Released: July 14, 2022

Expiration: July 13, 2023

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Lesley Scott

Lesley Scott

Shannon N. Westin

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Eisai Inc.

GlaxoSmithKline

ImmunoGen, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Nicoletta Colombo, MD: consultant: AstraZeneca, Clovis, Eisai, GlaxoSmithKline, ImmunoGen, Mersana, MSD, Pfizer, Roche.

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Shannon N. Westin, MD, MPH: researcher: AstraZeneca, Bayer, Clovis Oncology, Cotinga, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis; consultant: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRX, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis.